Abstract: The present disclosure generally relates to a two-stage system for detecting malicious nodes in Wireless Sensor Networks (WSNs), enhancing network security and resilience. The system employs a distributed approach, leveraging Cluster Heads (CHs) and a central server for efficient and accurate detection. Initially, sensor nodes are monitored for comprehensive node and network metrics, statistically ranked by significance in identifying malicious behavior. CHs perform a resource-aware first-stage detection based on their resource weight, filtering potential threats locally. Results are then aggregated at a server for a second-stage analysis using a hybrid Machine Learning (ML) and Deep Learning (DL) approach. This advanced analysis, combined with statistically relevant metrics, significantly improves detection accuracy.

Abstract: The present disclosure generally relates to a two-stage system for detecting malicious nodes in Wireless Sensor Networks (WSNs), enhancing network security and resilience. The system employs a distributed approach, leveraging Cluster Heads (CHs) and a central server for efficient and accurate detection. Initially, sensor nodes are monitored for comprehensive node and network metrics, statistically ranked by significance in identifying malicious behavior. CHs perform a resource-aware first-stage detection based on their resource weight, filtering potential threats locally. Results are then aggregated at a server for a second-stage analysis using a hybrid Machine Learning (ML) and Deep Learning (DL) approach. This advanced analysis, combined with statistically relevant metrics, significantly improves detection accuracy.

Abstract: The present invention relates to a system for fixing containers during handling and preventing them from swinging. The system of the present invention is characterized by the use of six wires instead of the eight wires used in the current systems to work on changing the movement of the tips of the spreader inward instead of outward. The system works to change the direction of movement of the spreader from the outside to the inside, by shifting the movement to the four sides of the spreader while tightening the wires towards the middle of the spreader in both horizontal and vertical directions.

Abstract: Broadly speaking, the present disclosure describes a method of modeling a temporal point process (TPP). For each sequence in the TPP, the method treats the sequence as one of a plurality of distinct tasks, and applies meta learning to the distinct tasks. Applying meta learning to the distinct tasks may comprise applying a neural process to the distinct tasks; the neural process may be an attentive neural process.

Abstract: A method for preparing a trained complete selective classifier can be applied to a trained complete selective classifier having an existing trained selection mechanism. The trained selective classifier is modified to disregard the existing trained selection mechanism and use, as a basis for an alternate selection mechanism, at least one classification prediction value, for example the predictive entropy or the maximum predictive class logit. Optionally, before modifying the trained selective classifier, the method commences with an untrained selective classifier, which may be trained with a modified loss function to obtain the trained selective classifier. The modified loss function has at least one added term, relative to an original loss function, and the at least one added term decreases entropy.

Abstract: A drug product comprising: a dry powder inhalation device containing one or more pharmaceutical compositions present therein, wherein the one or more pharmaceutical compositions comprise active ingredients (I) 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol, or a salt thereof, and (II) (6?,11?,16?,17?)-6,9-difluoro-17-{[(fluoromethyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate or a solvate thereof; a hygroscopic material; and a package which encompasses the dry powder inhalation device and the hygroscopic material defining an enclosed volume therein; wherein each of the active ingredients (I) and (II) are present in the same or different pharmaceutical compositions, and wherein the enclosed volume within the package exhibits a Relative Humidity of from 20% to 40%.

Abstract: A computer-implemented system and method for training a neural network with enforced monotonicity are disclosed. An example system includes at least one processor and memory in communication with said at least one processor, wherein the memory stores instructions for providing a data model representing a neural network for predicting an outcome based on input data, the instructions when executed at said at least one processor causes said system to: receive a feature data as input data; predict an outcome based on the input data using the neural network; compute a loss function based on the predicted outcome and an expected outcome associated with the input data, the loss function being dependent on a monotonicity penalty ? computed based on a set of training data including the feature data and on a set of random data; and update weights of the neural network based on the loss function.

Abstract: A drug product comprising: a dry powder inhalation device containing one or more pharmaceutical compositions present therein, wherein the one or more pharmaceutical compositions comprise active ingredients (I) 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy} hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol, or a salt thereof, and (II) (6?,11ß,16?,17?)-6,9-difluoro-17-{[(fluoromethyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate or a solvate thereof; a hygroscopic material; and a package which encompasses the dry powder inhalation device and the hygroscopic material defining an enclosed volume therein; wherein each of the active ingredients (I) and (II) are present in the same or different pharmaceutical compositions, and wherein the enclosed volume within the package exhibits a Relative Humidity of from 20% to 40%.

Abstract: A cranial cap dressing for dressing a craniotomy wound comprising a breathable elastic outer layer sized to fit snuggly on a human head of a patient and an absorbent inner layer attached to the breathable elastic outer layer.

Abstract: A drug product comprises a dry powder inhalation device having a pharmaceutical composition present therein, said pharmaceutical composition comprising a compound which is (6?,11?,16?,17?)-6,9-difluoro-17-{[(fluoromethyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate or a solvate thereof; a hygroscopic material, and a package which encompasses the dry powder inhalation device and the hygroscopic material defining an enclosed volume therein, wherein the enclosed volume exhibits a Relative Humidity of from 20% to 40%.

Abstract: A cranial cap dressing for dressing a craniotomy wound comprising a breathable elastic outer layer sized to fit snuggly on a human head of a patient and an absorbent inner layer attached to the breathable elastic outer layer.

Abstract: A cranial cap dressing for dressing a craniotomy wound comprising a breathable elastic outer layer sized to fit snuggly on a human head of a patient and an absorbent inner layer attached to the breathable elastic outer layer.

Abstract: A drug product comprises a dry powder inhalation device having a pharmaceutical composition present therein, said pharmaceutical composition comprising a compound which is (6?, 11?, 16?, 17?)-6,9-difluoro-17-{[(fluoromethyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1, 4-dien-17-yl 2-furancarboxylate or a solvate thereof; a hygroscopic material, and a package which encompasses the dry powder inhalation device and the hygroscopic material defining an enclosed volume therein, wherein the enclosed volume exhitbits a Relative Humidity of from 20% to 40%.

Abstract: A drug product comprises a dry powder inhalation device containing one or more pharmaceutical compositions present therein, wherein the one or more pharmaceutical compositions comprise active ingredients (I) 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol, or a salt thereof, and (II) (6?,11?,16?,17?)-6,9-difluoro-17-{[(fluoromethyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate or a solvate thereof; a hygroscopic material; and a package which encompasses the dry powder inhalation device and the hygroscopic material defining an enclosed volume therein; wherein each of the active ingredients (I) and (II) are present in the same or different pharmaceutical compositions, and wherein the enclosed volume within the package exhibits a Relative Humidity of from 20% to 40%.

Abstract: A training shoe includes an anchorage device (3) adapted secure to receive one or more elastic cords (5) against which a wearer may exert him or herself. Preferably, the anchorage device includes a hole (3) extending transversely through the sole (1) of the shoe and through which hole (3) one or more elastic cords (5) are threaded so as to form an elastic loop which may be pulled by the wearer as part of an exercise regime.